Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics

被引：0
|
作者：
Nael Al Koudsi
Jill C. Mwenifumbo
Edward M. Sellers
Neal L. Benowitz
Gary E. Swan
Rachel F. Tyndale
机构：
[1] University of Toronto,Centre for Addiction & Mental Health, and Department of Pharmacology
[2] University of California,Division of Clinical Pharmacology and Experimental Therapeutics, Medical Service, San Francisco General Hospital Medical Center, and Departments of Medicine, Psychiatry and Biopharmaceutical Sciences
[3] SRI International,Center for Health Sciences
[4] University of Toronto,undefined
来源：
European Journal of Clinical Pharmacology | 2006年 / 62卷
关键词：
CYP2A6; Nicotine metabolism; Polymorphism; Pharmacogenetics; Smoking;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：481 / 484
页数：3
相关论文
共 50 条
  • [31] In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population
    Djordjevic, Natasa
    Carrillo, Juan Antonio
    Gervasini, Guillermo
    Jankovic, Slobodan
    Aklillu, Eleni
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (06) : 571 - 578
  • [32] Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors
    Al Koudsi, Nael
    Hoffmann, Ewa B.
    Assadzadeh, Abbas
    Tyndale, Rachel F.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (03) : 239 - 251
  • [33] CYP2A6 slow nicotine metabolism is associated with increased quitting by adolescent smokers
    Chenoweth, Meghan J.
    O'Loughlin, Jennifer
    Sylvestre, Marie-Pierre
    Tyndale, Rachel F.
    PHARMACOGENETICS AND GENOMICS, 2013, 23 (04) : 232 - 235
  • [34] Isoflavones inhibit nicotine C-oxidation catalyzed by human CYP2A6
    Nakajima, M
    Itoh, M
    Yamanaka, H
    Fukami, T
    Tokudome, S
    Yamamoto, Y
    Yamamoto, H
    Yokoi, T
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (03) : 337 - 344
  • [35] Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6)
    Chen, Li-Shiun
    Bloom, A. Joseph
    Baker, Timothy B.
    Smith, Stevens S.
    Piper, Megan E.
    Martinez, Maribel
    Saccone, Nancy
    Hatsukami, Dorothy
    Goate, Alison
    Bierut, Laura
    ADDICTION, 2014, 109 (01) : 128 - 137
  • [36] Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism
    Yoshida, R
    Nakajima, M
    Watanabe, Y
    Kwon, JT
    Yokoi, T
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (05) : 511 - 517
  • [37] Disposition kinetics and metabolism of nicotine and cotinine in African American smokers: impact of CYP2A6 genetic variation and enzymatic activity
    Benowitz, Neal L.
    Helen, Gideon St.
    Dempsey, Delia A.
    Jacob, Peyton, III
    Tyndale, Rachel F.
    PHARMACOGENETICS AND GENOMICS, 2016, 26 (07) : 340 - 350
  • [38] Variation in CYP2A6 Activity and Personalized Medicine
    Tanner, Julie-Anne
    Tyndale, Rachel F.
    JOURNAL OF PERSONALIZED MEDICINE, 2017, 7 (04):
  • [39] Evaluating metronidazole as a novel, safe CYP2A6 phenotyping probe in healthy adults
    Stancil, Stephani L.
    Pearce, Robin E.
    Tyndale, Rachel F.
    Kearns, Gregory L.
    Vyhlidal, Carrie A.
    Leeder, J. Steven
    Abdel-Rahman, Susan
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (05) : 960 - 969
  • [40] CYP2A6 genetic variation and potential consequences
    Xu, C
    Goodz, S
    Sellers, EA
    Tyndale, RF
    ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (10) : 1245 - 1256
12345